Stop Corporate Inversions Act of 2026

The Stop Corporate Inversions Act of 2026, HR7493, aims to curb corporate inversions by amending the Internal Revenue Code. The bill specifically targets transactions where a U.S. company reincorporates abroad to reduce its U.S. tax burden. It does this by lowering the threshold for what constitutes a 'surrogate foreign corporation' from 80% to 50% ownership by former U.S. shareholders, and by expanding the definition of an 'expatriated entity' to include companies where the foreign parent is managed and controlled in the U.S. and has substantial business activities in the U.S. This means companies that have inverted and maintain significant U.S. operations will be treated as domestic corporations for tax purposes, negating the tax advantages of their inversion. This bill directly impacts the profitability of companies that have previously inverted or those considering such a move. The 'money trail' is a shift from reduced tax liabilities for inverted companies back to the U.S. Treasury. There are no direct appropriations or grants; instead, it is a revenue-generating measure for the government. Companies that have inverted to lower their effective tax rates will see those rates increase, directly reducing their net income. This change in tax treatment makes the U.S. a less attractive target for foreign acquisitions if the intent is to invert and reduce tax obligations. Historically, similar legislative efforts to curb inversions have had a direct impact. In 2014, the Treasury Department issued new regulations to make inversions more difficult, which led to several planned inversions being abandoned or restructured. For example, AbbVie ($ABBV) abandoned its $54 billion acquisition of Shire in October 2014, citing the new Treasury rules, which resulted in a $1.6 billion breakup fee. While specific stock price movements are harder to isolate due to broader market conditions, the regulatory tightening clearly deterred inversion activity and impacted M&A strategies. The American Taxpayer Relief Act of 2012 also included provisions to prevent inversions, though less stringent than HR7493. Specific companies that stand to lose include those that have completed inversions and maintain significant U.S. operations, such as Medtronic ($MDT), which inverted to Ireland in 2015 via its acquisition of Covidien, and Eaton ($ETN), which inverted to Ireland in 1997. Other companies like Perrigo ($PRGO) and Johnson Controls ($JCI) also completed inversions. While the bill does not retroactively undo the legal structure, it removes the tax benefits. Companies like Pfizer ($PFE), which attempted an inversion with Allergan in 2016 but abandoned it due to Treasury regulations, would have faced significant headwinds under this type of legislation. Companies in the healthcare sector ($PFE, $MDT, $SYK, $BMY, $ELV) and technology sectors, which have historically engaged in M&A with inversion potential, will face higher tax burdens if they have inverted or find future inversion strategies unviable. The bill's referral to the House Committee on Ways and Means, with Rep. Doggett (a known proponent of tax reform) as sponsor, indicates a serious legislative push. What happens next is committee consideration. If the bill passes the House Ways and Means Committee, it moves to a full House vote. If it passes the House, it then goes to the Senate. The timeline for such a significant tax bill is typically several months to a year, but the immediate impact is on corporate M&A strategies and tax planning for companies with foreign operations. Companies will begin to factor this increased tax risk into their valuations and strategic decisions immediately upon the bill's introduction and committee referral.